Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Standard BioTools Inc (NASDAQ: LAB) closed the day trading at $1.29 down -1.53% from the previous closing price of $1.31. In other words, the price has decreased by -$1.53 from its previous closing price. On the day, 1.26 million shares were traded. LAB stock price reached its highest trading level at $1.32 during the session, while it also had its lowest trading level at $1.27.
Ratios:
For a better understanding of LAB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.92 and its Current Ratio is at 5.16. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 16, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $3.50.TD Cowen initiated its Buy rating on April 16, 2024, with a $3.50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 09 ’25 when Casdin Partners Master Fund, L bought 100,000 shares for $1.29 per share. The transaction valued at 128,920 led to the insider holds 60,875,000 shares of the business.
Casdin Partners Master Fund, L bought 250,000 shares of LAB for $319,350 on Sep 04 ’25. The Director now owns 60,775,000 shares after completing the transaction at $1.28 per share. On Sep 03 ’25, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 250,000 shares for $1.27 each. As a result, the insider paid 316,400 and bolstered with 60,525,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 500413568 and an Enterprise Value of 182078080. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.19 while its Price-to-Book (P/B) ratio in mrq is 1.16. Its current Enterprise Value per Revenue stands at 1.057 whereas that against EBITDA is -1.495.
Stock Price History:
The Beta on a monthly basis for LAB is 1.31, which has changed by -0.328125 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, LAB has reached a high of $2.32, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is -1.73%, while the 200-Day Moving Average is calculated to be -2.90%.
Shares Statistics:
Over the past 3-months, LAB traded about 1.44M shares per day on average, while over the past 10 days, LAB traded about 1192580 shares per day. A total of 381.69M shares are outstanding, with a floating share count of 365.52M. Insiders hold about 4.31% of the company’s shares, while institutions hold 74.20% stake in the company. Shares short for LAB as of 1756425600 were 12169060 with a Short Ratio of 8.34, compared to 1753920000 on 12009245. Therefore, it implies a Short% of Shares Outstanding of 12169060 and a Short% of Float of 4.99.
Earnings Estimates
The current rating of Standard BioTools Inc (LAB) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.09 and -$0.09 for the fiscal current year, implying an average EPS of -$0.09. EPS for the following year is -$0.04, with 1.0 analysts recommending between -$0.04 and -$0.04.
Revenue Estimates
3 analysts predict $18M in revenue for the current quarter. It ranges from a high estimate of $18.3M to a low estimate of $17.7M. As of the current estimate, Standard BioTools Inc’s year-ago sales were $44.97MFor the next quarter, 3 analysts are estimating revenue of $19.3M. There is a high estimate of $20M for the next quarter, whereas the lowest estimate is $18.4M.
A total of 3 analysts have provided revenue estimates for LAB’s current fiscal year. The highest revenue estimate was $100.4M, while the lowest revenue estimate was $78M, resulting in an average revenue estimate of $86.37M. In the same quarter a year ago, actual revenue was $174.43MBased on 3 analysts’ estimates, the company’s revenue will be $79.73M in the next fiscal year. The high estimate is $81M and the low estimate is $78.7M.
